clarithromycin and cyclosporine

Clarithromycin inhibits CYP3A4 and P-glycoprotein (P-gp), both of which are involved in the metabolism and transport of cyclosporine. This inhibition leads to significantly increased plasma concentrations of cyclosporine, primarily by reducing its hepatic metabolism and intestinal efflux. The result is enhanced systemic exposure to cyclosporine, increasing the risk of toxicity.

Elevated cyclosporine concentrations can cause serious adverse effects, including nephrotoxicity, neurotoxicity (e.g. tremor, headache, confusion), hypertension, and electrolyte disturbances. Patients may develop reversible increases in serum creatinine and blood urea nitrogen. Severe cases can lead to irreversible renal damage, particularly with prolonged co-administration.

Avoid concomitant use of clarithromycin and cyclosporine if possible. If co-administration is considered necessary, reduce the cyclosporine dose empirically by approximately 50% and closely monitor cyclosporine trough levels, renal function, and blood pressure. Measure cyclosporine concentrations before starting clarithromycin, then twice weekly during co-administration, and after discontinuing clarithromycin. Adjust the cyclosporine dose to maintain therapeutic levels. Consider alternative macrolides with less CYP3A4 inhibitory activity, such as azithromycin, if appropriate.

This interaction is well established through multiple pharmacokinetic studies, case reports, and clinical experience. Clarithromycin-induced increases in cyclosporine concentrations of two- to five-fold have been consistently reported, and serious toxicity has been documented. Management strategies are widely supported in transplant guidelines and prescribing information.